|
Fulvestrant in hormone receptor-positive advanced breast cancer: A UK retrospective multicenter study. |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
Consulting or Advisory Role - Bristol-Myers Squibb; MSD; Novartis |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
Alicia Frances Clare Okines |
|
Research Funding - Pfizer (Inst) |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
Consulting or Advisory Role - Eisai; Genomic Health; Lilly; Novartis; Pfizer; Roche |
Speakers' Bureau - Lilly; Roche |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
Honoraria - Genomic Health; Roche |
Speakers' Bureau - Genomic Health; Roche |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
Honoraria - AstraZeneca; Lilly; Novartis; Roche |
Consulting or Advisory Role - AstraZeneca; Lilly; Novartis; Roche |